Menu
This security has been delisted
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Gensight Biologics SA

WKN: A2ANGZ / Name: Gensight / Stock / Biotechnology & Medical Research / Micro Cap /

€0.073
-5.320%

Cansino Biologics Inc.

WKN: A2PGFW / Name: Cansino Biologics Inc. / Stock / ? /

€3.71
2.260%

Mustgrow Biologics Corp.

WKN: A2PNS7 / Name: Mustgrow Biologics Corp. / Stock / ? /

€0.41
-0.970%

Pure Biologics S.a.

WKN: A2N9NP / Name: Pure Biologics S.a. / Stock / ? /

€0.76
-0.260%

Innovent Biologics, Inc.

WKN: A2N7N8 / Name: Innovent Biologics / Stock / Small Cap /

€8.55
-1.160%

Abcellera Biologics Inc.

WKN: A2QKXS / Name: Abcellera Biologics Inc. / Stock / ? /

€2.67
11.510%

Theriva Biologics Inc.

WKN: A40MGC / Name: Theriva Biologics Inc. / Stock / ? /

€2.42
-

Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider

Adma Biologics (ADMA) closed at $17.50 in the latest trading session, marking a +1.16% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.54%. Elsewhere, the Dow

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Adma Biologics (ADMA) closed at $16.96 in the latest trading session, marking a +1.37% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.5%. At the same time

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts